phrykt

DBV Technologies S.A. (DBVT): who owns it and who trades it

As of Nov 16, 2026, DBVT insiders reported 7 open-market sales worth $15.5M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Bpifrance EPIC (Other), with $15.5M. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling DBV Technologies

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DBVT

77 funds and institutions reported DBVT shares worth $344M at the end of Q2 2026, about 7% of the company. The largest holder is Mpm Bioimpact LLC with 1.2%.

Funds and institutions (13F) 7%Everyone else 93%

10 largest owners, by share of the company

Mpm Bioimpact LLC1.2%
Siren, L.L.C.0.6%
Vivo Capital, LLC0.6%
Perceptive Advisors LLC0.6%
Baker Bros. Advisors LP0.5%
Artisan Partners Limited Partnership0.5%
UBS Group AG0.4%
Morgan Stanley0.3%
Logos Global Management LP0.3%
Patient Square Capital LP0.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Mpm Bioimpact LLC3.67M1.24%$60.1M-30%
Siren, L.L.C.1.86M0.63%$30.5MNo change
Vivo Capital, LLC1.84M0.62%$30.3M-31%
Perceptive Advisors LLC1.65M0.56%$27.1M+71%
Baker Bros. Advisors LP1.46M0.49%$24MNo change
Artisan Partners Limited Partnership1.37M0.46%$22.5M-38%
UBS Group AG1.31M0.44%$21.5M+1551%
Morgan Stanley954,9080.32%$15.7M+554%
Logos Global Management LP915,0000.31%$15MNew
Patient Square Capital LP909,4740.31%$14.9M+31%
Octagon Capital Advisors LP574,2000.19%$9.4MNo change
ADAR1 Capital Management, LLC528,2950.18%$8.7M-48%
Redmile Group, LLC410,4400.14%$6.7M-16%
Duquesne Family Office LLC383,3630.13%$6.3MNo change
Ameriprise Financial Inc378,4970.13%$6.2M+64%
Millennium Management LLC267,7830.09%$4.4M-16%
Elmind Capital, LP265,0000.09%$4.3MNo change
Jane Street Group, LLC223,9150.08%$3.7M+1884%
Ishara Investments LP184,5000.06%$3M+80%
Yiheng Capital Management, L.P.170,1420.06%$2.8MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DBVT insiders reported $0 of open-market purchases and $15.5M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$15.5M
7 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 29, 2026
Filed Jul 31, 2026

Purchases and sales by month

$15.5M$15.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 29, 2026Pharis MohideenChief Medical OfficerSale464$2.70$1.3KForm 4
Jan 29, 2026Pharis MohideenChief Medical OfficerSale534$4.86$2.6KForm 4
Dec 18, 2025Bpifrance EPIC +4OtherSale1.29M$4.19$5.4MForm 4
Dec 17, 2025Bpifrance EPIC +4OtherSale40,000$5.28$211KForm 4
Dec 17, 2025Bpifrance EPIC +4OtherSale2.04M$4.84$9.9MForm 4
Nov 21, 2025Pharis MohideenChief Medical OfficerSale1,624$2.77$4.5KForm 4
Nov 20, 2025Pharis MohideenChief Medical OfficerSale6,496$2.88$18.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Bpifrance EPICOther–$15.5MDec 18, 2025
Pharis MohideenChief Medical Officer–$27.1KJul 29, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DBVT short interest

Low short interest. 0.3% of DBVT shares are sold short: about 1 share in 390. Over the last 12 reports the number of shares short went down 78%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 806,674 DBVT shares were sold short, 0.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 483,590 shares, buying them all back would take about 1.7 trading days (days to cover).

Shares short, % of all shares

0.26%May 15Oct 300.66%

Days to cover

1.7May 15Oct 3011.3

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 2026806,6740.26%-7%483,5901.7
Oct 15, 2026872,075–-22%438,2252.0
Sep 30, 20261.12M–-17%285,0343.9
Sep 15, 20261.35M–-15%410,5433.3
Aug 31, 20261.58M–-3%163,2899.7
Aug 14, 20261.63M–-12%411,3204.0
Jul 31, 20261.85M–+26%370,2935.0
Jul 15, 20262.94M0.50%+13%187,6617.8
Jun 30, 20262.60M0.44%-9%352,0483.7
Jun 15, 20262.85M0.48%-15%259,2945.5
May 29, 20263.33M0.56%-7%282,4365.9
May 15, 20263.60M0.61%-1%179,25510.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

DBV Technologies company events

DBV Technologies filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 28, 2026.

  1. Oct 28, 2026ResultsReleased financial results. Filing
  2. Sep 30, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing
  3. Jul 16, 2026ResultsReleased financial results. Filing
  4. Jun 29, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 Through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing.” A copy of the press release is attached as… Filing
  5. Jun 5, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  6. Jun 3, 2026VoteReported shareholder vote results. Filing
  7. May 5, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  8. Apr 30, 2026ResultsReleased financial results. Filing
  9. Mar 26, 2026ResultsReleased financial results. Filing
  10. Mar 2, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Filing
  11. Jan 20, 2026AnnouncementDBV Technologies S.A. issued a press release entitled “DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March Financing.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form… Filing
  12. Dec 16, 2025AnnouncementDBV Technologies S.A. issued a press entitled “DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN ® Peanut Patch in Peanut Allergic Children Aged 4-7 Years.” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

DBV Technologies financials

Famous investors that hold DBVT

3 of the 50 well-known investors we track reported holding DBVT in their latest 13F filing. The largest position is Israel Englander's, worth $6.5M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026552,991$6.5M0.0%+107%
Ken Griffin · Citadel AdvisorsQ3 2026276,134$3.2M0.0%+1112%
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026173,028$2M0.0%-55%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DBVT in the last 120 days.

FiledHolderFormStake
Nov 13, 2026MPM BioImpact LLC13G/A4.8%
Nov 13, 2026MPM BioImpact LLC13G/A4.8%
Nov 12, 2026Invus Public Equities, L.P.13G/A7.3%
Nov 12, 2026Invus Public Equities, L.P.13G/A7.3%

Questions about DBV Technologies S.A. (DBVT) stock

Who owns the most DBVT stock?

The largest reported owner of DBV Technologies S.A. (DBVT) is Mpm Bioimpact LLC, with 1.2% of the company. In total, 77 funds and institutions reported holding DBVT at the end of Q2 2026, together about 7% of the shares. See the largest owners.

Are DBVT insiders buying or selling?

In the last 12 months, DBVT insiders reported no open-market purchases and 7 sales worth $15.5M. The latest trade was on Jul 29, 2026. See every trade.

What is the short interest in DBVT?

As of Oct 30, 2026, 806,674 DBVT shares were sold short, 0.3% of the shares outstanding, down 7.5% from the report before. At the average daily volume of 483,590 shares, buying them all back would take about 1.7 trading days (days to cover). See the history.

Which famous investors hold DBVT?

3 of the 50 well-known investors we track reported DBVT in their latest 13F filing, including Israel Englander, Ken Griffin, Stanley Druckenmiller. The largest position is worth $6.5M. See all holders.

Executive pay

DBV Technologies's chief executive was paid a total of $3.4M for the year ended Dec 31, 2025, up 107% from $1.6M the year before. In the last 12 months, DBV Technologies's executives and directors bought no stock on the open market and sold $15.5M.

Chief executive, total pay$3.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$7.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.